- Previous Close
0.0826 - Open
0.0826 - Bid 0.0708 x --
- Ask 0.1020 x --
- Day's Range
0.0824 - 0.0826 - 52 Week Range
0.0365 - 0.1244 - Volume
50,500 - Avg. Volume
20,211 - Market Cap (intraday)
4.075M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company's lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer's disease and autism spectrum disorder, as well as depression and anxiety, ADHD, non-neurological conditions of cancer, and non-alcoholic steatohepatitis. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.
marvelbiotechnology.comRecent News: MBCOF
View MorePerformance Overview: MBCOF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBCOF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBCOF
View MoreValuation Measures
Market Cap
4.05M
Enterprise Value
5.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--